Elotuzumab in combination with pomalidomide and dexamethasone for the treatment of multiple myeloma-Reference-Cited by-同舟云学术

Elotuzumab in combination with pomalidomide and dexamethasone for the treatment of multiple myeloma

Published:2019-11-02 Issue:11 Volume:19 Page:921-928
ISSN:1473-7140
Container-title:Expert Review of Anticancer Therapy
language:en
Short-container-title:Expert Review of Anticancer Therapy

Author:

Eleutherakis-Papaiakovou Evangelos¹,Gavriatopoulou Maria¹^ORCID,Ntanasis-Stathopoulos Ioannis¹^ORCID,Kastritis Efstathios¹^ORCID,Terpos Evangelos¹,Dimopoulos Meletios A¹^ORCID

Affiliation:

1. Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece

Publisher

Informa UK Limited

Subject

Pharmacology (medical),Oncology

Link

https://www.tandfonline.com/doi/pdf/10.1080/14737140.2019.1685879

Reference91 articles.

1. Multiple Myeloma: Charging Toward a Bright Future

2. Multiple Myeloma

3. Updated Diagnostic Criteria and Staging System for Multiple Myeloma

4. Importance of Achieving a Complete Response in Multiple Myeloma, and the Impact of Novel Agents

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Medicinal chemistry perspective on cGAS-STING signaling pathway with small molecule inhibitors;European Journal of Medicinal Chemistry;2022-12

2. Advances in Immunosuppressive Agents Based on Signal Pathway;Frontiers in Pharmacology;2022-05-26

3. Toxicity management strategies for next-generation novel therapeutics in multiple myeloma;Therapeutic Advances in Hematology;2022-01

4. Improving outcomes for patients with relapsed multiple myeloma: Challenges and considerations of current and emerging treatment options;Blood Reviews;2021-09

5. A sensitive and validated LC-MS/MS method for high-throughput determination of pomalidomide in human plasma and pharmacokinetic studies;Chinese Chemical Letters;2021-07